CANCER CONFERENCES

Prof. Dr. Uwe Zangemeister-Wittke, PhD
Group leader Experimental Pharmacology and Tumour Pharmacology, University of Bern and Zürich, Switzerland.

Uwe Zangemeister-Wittke has a strong interest in tumour-targeted therapies using antibodies and antibody-based drug delivery systems as well as in the molecular mechanisms regulating anti-apoptosis and drug resistance in solid tumours.

Prior to joining the Institute of Pharmacology in Bern and working as a group leader in the distinguished protein engineering team of Prof. Dr. Andreas Plückthun at the Institute of Biochemistry in Zürich in 2005, he was deputy head in the Molecular Oncology Laboratory at the University Hospital Zürich. A major focus of his targeted cancer therapeutics team is the generation of antibody-like Designed Ankyrin Repeat Proteins and of nanomedicines targeting the tumour-associated antigens EpCAM and Her2. In addition to his research activities in the cancer therapy field, Uwe Zangemeister-Wittke is a lecturer at the medical faculties of both universities in tumour biology, tumour pharmacology, and cardiovascular and general pharmacology.

Dr. Sergej Kiprijanov
Vice President of Discovery Research and Preclinical Development at Affitech AS, Oslo, Norway.

Dr Kiprijanov brings to the company a wealth of experience in the antibody therapeutic field. Previously CSO of Novoplant GmbH, a German plant biotech company developing antibodies for oral applications, Dr. Kiprijanov was also Head of Research and Development with Affimed Therapeutics AG in Heidelberg, Germany, focusing on engineering human antibodies and antibody fragments for cancer indications. Before that, Dr. Kiprijanov was with the German Cancer Research Center (DKFZ), Heidelberg, Germany, where he played a key role in creating the novel bispecific antibody formats useful for tumor therapy.

Prior to moving to Germany, Dr. Kiprijanov headed the Laboratory of Cellular Engineering at the Russian State Research Center of Virology and Biotechnology "Vector" (Novosibirsk, Russia). Dr. Kiprijanov graduated in Biochemistry and Molecular Biology from Novosibirsk State University (Novosibirsk, Russia) in 1983 and received his PhD degree from the Institute of Genetics and Selection of Industrial Microorganisms (Moscow, Russia) in 1990. Dr. Kiprijanov has authored more than 60 research articles, reviews and book chapters and is named as an inventor on 20 patents and patent applications.

Jennie P. Mather, PhD
Founder, President, CSO and Director, USA.

Dr. Mather has over thirty years of experience in cell biology research and drug development. In 1979, Dr. Mather joined the faculty of The Rockefeller University. From 1984 to 1999, at Genentech, she worked on eight currently marketed recombinant protein products. Dr. Mather left Genentech to found Raven biotechnologies, inc., a company focused on discovery of cancer drug targets and antibody therapeutics using an integrated cell biology-based approach.

Dr Mather served as CEO from 1999-2006 when she raised >$100M and grew Raven to a company of 70 people. Raven's first product, RAV12, is in phase 2 clinical trials for pancreatic cancer, a second product is in pre-clinical development, and a strong pipeline follows. Dr. Mather is an inventor on >40 patents, has authored or edited 5 books and more than 150 publications. Among other awards, in 2002, Dr. Mather was named one of the Top Ten Innovators by Red Herring Magazine, and in 2005, named a Technology Pioneer by the World Economic Forum.

Roger Schibli
ETH Zürich, Switzerland.

Roger Schibli has been Assistant Professor for Therapeutics Technologies II at the Institute of Pharmaceutical Sciences of the Swiss Federal Institute of Technology Zürich (ETH Zürich), since October 2004. He is also head of the group Radionuclide Chemistry of the Center for Radiopharmaceutical Science at the Paul Scherrer Institute.

Born 1968 in Leibstadt, Switzerland professor Roger Schibli studied Chemistry at the University of Basel from 1988 to 1992. He did his diploma work in physical Chemistry in the laboratories of Prof. Fabian Gerson. From 1993 until 1996 he performed his doctoral thesis under the supervision of Prof. Thomas Kaden at the University of Basel. The subject of his thesis concerned the organometallic Chemistry of the elements Technetium and Rhenium. After his graduation, he spent two years at the University of Missouri-Columbia, MO as a post-doctoral fellow. The project was dedicated to the synthesis of novel, water-soluble transition metal complexes for potential use in nuclear medicine. Since 1999 Roger Schibli is head of the group Radionuclide Chemistry at the Center for Radiopharmaceutical Science at the Paul Scherrer Institute. His habilitation thesis was accepted in 2003 by the Department of Chemistry and Applied Biosciences of the ETH Zurich.

Prof. Schibli' s research activities concentrate on the development of radioactive labeled, small biomolecules (vitamins, nucleosides and peptides) for targeted diagnosis and therapy of cancerous diseases with transition metal isotopes. Apart from the chemical-synthetic and radioactive modification of molecules, his work emphasizes on the biological and pharmacological characterization and optimization of the radioactive compounds in vitro and in vivo. New medically relevant radionuclides for pre-clinical and clinical studies are produced at the large research facilities of the Paul Scherrer Institute (Cyclotron, SINQ) under the guidance of Prof. Schibli.

Konstantinos Syrigos, MD, PhD
Professor and Head, Oncology Unit GPP, Athens School of Medicine, Greece
Visiting Professor of Thoracic Oncology, Yale School of Medicine, CT, USA.

Professor Kostas Syrigos was born in Athens, in 1964. He graduated from Athens School of Medicine in 1988. He was trained in Internal Medicine at Laikon University Hospital (Athens University) and in Medical Oncology at Hammersmith Hospital (London University). He got his MD thesis with distinction from the Athens School of Medicine, in 1995 and his PhD thesis from the Imperial College of Science, Technology and Medicine, London University, in 2000. He worked as Medical Oncologist Senior Registrar at Hammersmith and St Bartholomew's Hospitals, in London and at Sotiria General Hospital, in Athens.

In 2002 he was appointed Ass. Professor of Oncology in Medicine and Head of the Sotiria Oncology Unit. From 2006 he is also visiting Professor of Thoracic Oncology at Yale University, CT, USA. His main fields of interest are Thoracic Oncology and Drugs Development.

He participated in several international clinical trials Phase I-IV. He is member of the editorial board and has served as reviewer in numerous journals. He is the editor of 6 International Scientific Volumes, including the Tumors of The Chest (2006, Springer). He has contributed 80 chapters in international books and he is the author of 155 peer-review articles.

Dr David Blakey PhD
Chief Scientist, Cancer and Infection Research Area, AstraZeneca, UK.

Dr Blakey has over 20 years experience in therapeutic antibodies. He worked on the optimisation and pharmacology of ricin immunotoxins at the ICRF and then joined AstraZeneca in 1987 where he initially worked on the development of immunotoxins and then on Antibody Directed Enzyme Prodrug therapy in collaboration with the Cancer Research Campaign. More recently Dr Blakey led the establishment and scientific leadership of AstraZeneca's collaboration with Abgenix/Amgen as well as having a science leadership role within AstraZeneca in the area of therapeutic vascular modulation. Since Feb 2008 he has been on secondment to MedImmune (AstraZeneca's fully owned biologics company) providing global scientific leader ship for Medimmune oncology biologics projects and target selection.

Klaus Bosslet, PhD
Head of Therapeutic Research Oncology, Bayer Schering Pharma AG, Germany.

Responsibilities and Expertise:

Headed cancer research projects as well as cancer research and development teams for more than 25 years.
Lead small molecule and antibody projects in pharmaceutical companies (Behringwerke AG, HMR, and both Germany) as well as oncolytic virus projects in Biotech industry (ProVirus Inc, USA).
Built a competitive oncology research and development pipeline for Schering containing both small molecule as well as antibody projects.
Successfully managed a global cancer research function at Schering AG which was supported by 80 cancer research FTEs (budget: 13 Mio€) as well as 100 FTEs from research center functions (total responsibility: 180 employees).
Managed and built the oncology research team at Bayer Schering Pharma (105 FTEs) supported by 180 FTEs from central functions. Carries responsibility for the oncology research project pipeline up to the level of preclinical development containing both small molecule as well as antibody projects in 3 distinct disease mechanisms.

Giovanni Paganelli, MD.
Director of the Nuclear Medicine Division at the European Institute of Oncology, Italy.

Director of the Nuclear Medicine Division at the European Institute of Oncology (Milan, Italy), he graduated Doctor of Medicine and Surgery at the University of Bologna, subsequently specializing in Geriatrics and then Nuclear Medicine.

Between 1987 and 1988, he worked with the Oncology Group at the Hammersmith Hospital, Royal Postgraduate Medical School of London, perfecting a new technique (based on the avidin-biotin system) for tumour imaging and therapy using monoclonal antibodies.

Research Assistant and person in charge of clinical activity of the Nuclear Medicine Department at the Scientific Institute H San Raffaele (Milan, Italy) from 1989 to 1994.

His main field of interest is "in-vivo" application of the avidin-biotin system in the diagnosis and therapy of solid tumours and peptide receptor mediated radiotherapy (RMRT). He has pioneered the use of 90Y-Biotin in the antibody guided radiotherapy of gliomas.

Recently he optimised a lymphoscintigraphic technique for the detection of Sentinel Node in breast cancer. He also developed a new technique, called ROLL, to localize non palpable lesions in breast cancer.

The results of these studies (more than 170 articles) have been published in the major international scientific journals. Moreover, he owns eight scientific patent rights.

Invited speaker at several Italian and International Congresses and Symposia. In 1998 he won the prize "Marie Curie Award" fixed by the European Association of Nuclear Medicine. From February 2001 to December 2003 he has been an Expert of the Consiglio Superiore di Sanità.

At present, he is investigating a new receptor mediated radionuclide therapy using labelled 90Y/177LU-biotin for accelerated radiotherapy in breast cancer (IART ) after conservative surgery.

Efstathia Giannopoulou
University of Patras, Greece.

Current position (2003-…):
Researcher of Hellenic Cooperative Oncology Group (HECOG) in Clinical Oncology Laboratory, Department of Medicine, Division of Oncology, University of Patras, Greece.

Education:
1998: Diploma in Chemistry, Department of Chemistry, University of Patras, Greece
2000: M.Sc. in Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece
2003: PhD in Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

Publications
Refereed journal papers: 9
Referred papers in international and national conference proceedings: 14

Conference Participation/Attendance:
Presentations in international and national conferences: 32

Professional Affiliations:
Greek Chemist Association

Awards/Honours:
1998: Fellowship from I.?.?. (Institute of Greek State Fellowships)
2001: Fellowship for young researchers from ECCO 11, Lisbon, Portugal, October 21-25.
2002: Fellowship from Onasis foundation for participation in summer school "Cell signaling in health and disease".
2002: Award "Sofia Kakari" in 3rd national conference of oxidative stress, Athens, October 3-5.
2006: 3rd award in 6th national conference of cancer markers and targeted therapy, Athens, November 23-26.
2008: Award in 9th national conference of radiotherapy, Alexandroupolis, June 19-22.

Teaching Activities:
1999-2003: Participation in undergraduate teaching of "Biology approach in Pharmacy" and "Molecular Pharmacology" (laboratory practice), Department of Pharmacy, University of Patras, Greece.
2006-2008: Participation in course of "Radiobiology - Radiotherapy - Radioprotection", Department of Medicine, University of Patras, Greece.

Gregory P. Adams, PhD
Member with tenure Department of Medical Oncology, Division of Medical Sciences, Fox Chase Cancer Centre, USA

Dr. Adams received his B.A. in Biology at the University of California at Santa Cruz. As a graduate student in Dr. Sally DeNardo's laboratory at the University of California at Davis, his research involved preclinical tumour targeting with radiolabel monoclonal antibodies, focusing on the interactions between the antibodies and receptors on the liver. After receiving his PhD in Immunology in 1991, he joined the Fox Chase Cancer Centre as a Postdoctoral Fellow in Dr. Louis Weiner's group.

His postdoctoral research focused on tumour targeting using engineered antibody fragments (single-chain Fv molecules).
Dr. Adams joined the faculty of the Department of Medical Oncology at Fox Chase Cancer Centre in 1994 with the rank of Assistant Member was promoted to Associate Member in 2001 and to Member with Tenure in 2008. His current research focuses on the characterization of the properties required for efficient tumour-targeting by engineered antibody-based molecules, the development of alpha-emitter and beta-emitter-based radioimmunotherapy strategies including the development of radioactive nanoparticle immunoconjugates, ImmunoPET imaging using engineered antibody fragments and the detection of circulating tumour antigens using piezoelectric immuno-nanocantilevers.

Maureen O' Sullivan, PhD
Genzyme Europe Research, UK

Genzyme Europe Research is Genzyme's first dedicated research and development facility in Europe based on the Cambridge Science Park in the UK.

The science team is currently focused on Antibody Technology. Additional complementary therapeutic technologies will be imported to increase the repertoire of the team as opportunities arise. The team is using phage display technology to create reagent antibodies for target validation purposes as well as candidate therapeutic antibodies to targets of interest. Both single chain variable domain (scFv) phage display libraries, as well as FAb phage libraries are being employed.

A close working relationship exists between the Cambridge Team and the Framingham (MA) based Molecular Immunology and New Protein Therapeutics Groups.

Targets of interest to the Oncology, IMD and Renal Biology Portfolios have been identified and efforts are underway to create single chain and FAb fragments to these targets. Following attainment of proof of concept in pre-clinical models, a major goal for the Cambridge team will be the use of Antibody Technology to create candidate therapeutic antibodies for use in clinical trials. The Cambridge BMRA (Bio-Medical and Regulatory Affairs) group conduct global clinical trials, obtain regulatory approval for new medicines and perform all regulatory activities, for many countries. Therapeutic areas covered include Biosurgery, Oncology and Renal medicine.

Dominic White
Genzyme Europe Research, UK.

Continuing on from a science-oriented education, I studied Biochemistry with Cell Biology at the University of Leeds, obtaining a summer studentship to undertake cancer research in an academic lab. An optional year of industrial experience at AstraZeneca (Loughborough) propelled me into my first scientific job in industry at Unipath (Bedford). Working as a research scientist, I was responsible for the small-scale purification and Q.C. assessment of novel monoclonal antibodies for Unipath's R&D Laboratories. After a brief stint in industry, I decided to return to academic research, and joined Dr. Norman's Integrin Cell Biology Lab (University of Leicester) as a Welcome Trust funded Research Assistant/ MPhil student. After nearly three years of research I relocated with Dr. Norman' s group to the Beatson Institute for Cancer Research (Glasgow) for a further year. After acquiring a broad base of industrial and academic experience, I decided to return to England and join Genzyme (Cambridge) as a research associate. After a successful 1st year, with a promotion to Senior Research Associate, I'm looking forward to an interesting and rewarding career in antibody therapeutics.

Spyros Stylianou
Trojantec Ltd., Cyprus.

I studied for my undergraduate degree in Molecular Biology at the Long Island University. I was awarded my Masters Degree in Recombinant DNA Technology from The New York University and my PhD Degree from The University of Manchester for my studies in the role of Notch signalling in human breast cancer. My primary research interest is breast cancer. During my post doctoral work, I made a breakthrough in breast cancer research showing that Notch signalling is responsible for breast cancer in humans. I demonstrated that Notch1 is a proto oncogene involved in the aetiology of human breast cancer. In addition, I identified the molecular mechanisms by which Notch signalling transforms cells and protect cancer cells from drug induced apoptosis. I demonstrated that Notch, via the AKT pathway, suppresses p53 activation. More significantly, using animal models, I demonstrated that attenuation of Notch signalling reverts the transformed phenotype of human breast cancer cells and inhibits tumour formation in vivo, suggesting that inhibition of Notch signalling can pose a therapeutic strategy for this disease. I presented my research at various symposiums and scientific meetings during my graduate and post graduate studies. I presented invited talks at the Harvard Medical School, the Rockefeller University, and the Mount Sinai School of Medicine.

I dedicated my research efforts in the fight against breast cancer. I worked extensively in elucidating the genetic origins of breast cancer. I maintain an active research program investigating the molecular pathogenesis of breast cancer and treatment. My scientific interests are centred upon the way in which the Notch signalling pathway regulates stem cells and induces breast cancer in humans. I have taken novel approaches to creating better, more accurate models of breast cancer in mice.

My present and future goal is to continue the battle against breast cancer. As a cancer researcher, I am committed to maintaining this high standard of expertise. My vision is to be able to live in a time when cancer will no longer be a sentence of death or a cause of suffering for anyone.

Dr, Gregory Sivolapenko
Associate Professor, Dept. of Pharmacy, Head of the Pharmacokinetics Laboratory, University of Patras, Greece

Dr. Gregory Sivolapenko qualified in Pharmacy from the University of Athens in 1984 and obtained his PhD in Medicine (Immunology and Clinical Oncology) from the Royal Postgraduate Medical School (currently Imperial Medical School), University of London, UK, in 1990. During the period 1985-1990 he had worked as Research Fellow at the Hammersmith Hospital in London and at the Imperial Cancer Research Fund (UK).

Over the last twenty years, Dr. Sivolapenko has researched into cancer in the UK and Greece, with particular interest in tumour targeting using monoclonal antibodies and novel antibody-derived molecules. His basic and clinical research has resulted in a large number of publications at international medical journals and books. Dr. Sivolapenko has presented his studies as invited speaker at many international medical conferences and meetings. In recognition of his innovative research projects Dr. Sivolapenko received grants from several bodies including the Cancer Research Campaign (UK) and the European Commission.

Dr. Sivolapenko has gained international pharmaceutical product development and international medical/marketing experience through his employment and/or advisory position in a number of pharmaceutical companies. Dr. Sivolapenko has extensively researched in the area of late preclinical and early clinical drug development. He is founding member and member of the board of directors of several pharmaceutical research companies. Dr. Sivolapenko is also a member of the European Forum of Good Clinical Practice and participates at the Ethics Committees steering group. He is also guest lecturer at the School of Pharmacy and the Medical School, University of Athens, the Agricultural University of Athens, and evaluator of research proposals at the European Commission. Since March 2005, Dr. Sivolapenko holds the position of Associate Professor at the Dept. of Pharmacy and Head of the Pharmacokinetics Laboratory, University of Patras, Greece.

Prof. Dr. Stefan Dübel
Technical University of Braunschweig, Germany.

Dr. Stefan Dübel is Full Professor of Biotechnology and Director of the respective department at the Technical University of Braunschweig, Germany (http://www.bbt.tu-bs.de/Biotech). Prof. Dübel serves in boards of scientific journals and as consultant to biotech and pharma companies. Further, he is founder and coordinator of the "Antibody factory" of the German National Gemome Research Network.Further, he is founder and coordinator of the "Antibody factory" of the German National Gemome Research Network and editor of the three volume "Handbook of Therapeutic Antibodies" and other antibody engineering books.

After obtaining his PhD from the University of Heidelberg, in 1989 he joined the German Cancer Research Centre (DKFZ) where he co-pioneered in vitro antibody selection technologies, resulting in several key inventions including antibody phage display (e.g. US Patent 5849500) and antibody libraries with randomised CDRs (e.g. US Patent 5840479). His lab continued to contribute to multiple topics related to human antibody engineering and phage display, e.g. Hyperphage technology (2001), single chain Fab fragments (2006) and targeted RNases for cancer therapy (2008). Further contributions were made to the fields of human IgG production, infectious disease research, novel recombinant production systems (e.g. in Bacillus megaterium), and nanobiotechnology. His work resulted in 140+ publications and 20 patent applications.

Mikaela Friedman
Royal Institute of Technology, Sweden.

I attended the Royal Institute of Technology (KTH) in Stockholm, Sweden, where I received a Master of Science in Chemical Engineering, focusing on Biotechnology in 2002. The studies in Biotechnology were mainly performed at the Flinders University of Adelaide, Australia. I did my diploma work at the Department of Molecular Biotechnology (KTH) with the title "Applying biotin-streptavidin binding for iscom incorporation of recombinant immunogens".

I worked in the Human Proteome Resource Center, Royal Institute of Technology, for six month doing laboratory work with large-scale protein production and purification, analysis of protein and purification of antibodies. I then attended the group of Professor Stefan Ståhl at the Department of Molecular Biotechnology (KTH), where I obtained my PhD in 2008. My dissertation is titled "Affibody molecules targeting the epidermal growth factor receptor for tumor imaging applications". The focus of my research has mainly been in protein engineering and selection and characterization of targeting agents for molecular diagnostics of tumours.

Dr Christina Kousparou
Trojantec Ltd., Cyprus.

Dr. christina Kousparou obtained her BSc (Hons) in Genetics from Leicester University and DIC and PhD from Imperial College, London. The latter was awarded for studies on the development of antibody-directed therapies for cancer treatment. She worked at Imperial College as a post-doctoral scientist and then returned to Cyprus as an Associate to the Bank of Cyprus Oncology Centre and as Research Director of the hosted Cancer Research Laboratory.

Current research interest revolves around "trojan" peptides, a family of proteins that have been demonstrated to translocate across biological membranes of eukaryotic cells by an energy-independent pathway. Some of these molecules have already been successfully used to intracellularly deliver macromolecules, with promising therapeutic potential. In collaboration with the clinical staff of The Bank of Cyprus Oncology Centre, she has been investigating the significance of certain markers in diagnosing disease, monitoring treatment and predicting progression. She is part of an international group (Network of Excellence), TRANS-BIG, funded by the European Union for conducting a Phase III Clinical Trial in node-negative breast cancer patients, and a STREP also funded by the European Union developing immunophotodynamic therapy of cancer. Additional laboratory research grants come from The Research Promotion Foundation of Cyprus and local and European Venture Capital Groups. Her work has been presented in several international conferences and published in scientific journals.

She is a Visiting Lecturer at The Faculty of Sciences of Imperial College, London, for the Course 'Biotechnology and Business', teaching final year undergraduates in the area of biotechnology and drug development, focusing on proteins, antibodies, small molecules and stem cells. In addition, as from 2007, she is a Visiting Lecturer at The Faculty of Health Sciences of The Cyprus University of Technology, teaching 'Biology and Biochemistry'.

She is a Fellow of The Institute of Biomedical Scientists (FIBMS), and a Member of The American Association of Cancer Research (AACR), The Association of Clinical Biochemists (ACB) and The European Society for Medical Oncology (ESMO).

Dr. Pablo Umaña
Head of Research, GlycArt Biotechnology AG (Roche Group), Switzerland.

Obtained PhD (Chemical Engineering and Biology) from the California Institute of Technology in 1998 and was post-doctoral research fellow in molecular medicine at the University of Manchester, U.K. Co-founded GlycArt Biotechnology AG, Zurich in 2001, a company spinning out of research carried out at the ETH-Zurich.

Chief Scientific Officer at GlycArt since foundation, leading research and development of a new generation of engineered therapeutic antibodies. To date he continues to lead research and development at GlycArt as part of the Roche Group, after acquisition of GlycArt by Hoffmann La Roche AG in 2005. Led the GlycArt team that discovered and initially developed GA101, a 3rd generation CD20 antibody for the treatment of B-cell malignancies and autoimmune diseases. Member of the Roche team currently developing GA101.

Fabrice Le Gall, PhD
Affimed Therapeutics, Germany.

After studying the molecular biology of eukaryotes and immunology at the University Victor Segalen, Bordeaux (France), I received my PhD in 1998 for research on transgenic plants expressing recombinant antibodies at the National Institute for Agronomic Research (INRA), Bordeaux (France). This research performed during my Ph.D study was awarded the Silver medal of the French Agricultural Academy.

In late 1998, I moved to the German Cancer Research Center (DKFZ) in Heidelberg (Germany) in the research group "Recombinant Antibodies" of Prof. Melvyn Little to do a postdoc. The project research was the development of multivalent recombinant antibodies for tumour targeting.

In September 2000, I joined the Engineering group of Affimed Therapeutics. In 2004, I was appointed Head of the Engineering Group responsible for the production and purification of the recombinant proteins.

Evangelos Briasoulis, MD, PhD
Associate Professor of Oncology, University of Ioannina, Greece.

Education- Profession:

1971-1975 School of Theology, University of Athens, Greece
1976-1982 Medical School, University of Athens
1982-1984 Public Health service
1984-1989 Internal Medicine. Senior House Officer, 1st Public General Hospital of the National Insurance Institution, Athens
1989 Board certified in Internal Medicine
1989-1990 Head in Internal Medicine, Public Health Centre, Aliartos Viotias
1990-1993 Senior Registrar in Medical Oncology, Ioannina University Hospital
1993 Board certified in Medical Oncology, European Society of Medical Oncology [ESMO]
1993-1994 Medical Oncologist, Ioannina University Hospital
1994-1995 Clinical Research Fellow, Phase I Unit, Centre for Cancer Therapeutics, ICR and Royal Marsden Hospital, London
1996-2002 Senior Medical Oncologist, Head of the Phase I Unit, Ioannina University Hospital
2002-2008 Assistant Professor of Oncology, Medical Scholl, University of Ioannina
2008- cont Associate Professor of Oncology, Medical Scholl, University of Ioannina
2006- cont. ESMO Faculty Member in Scientific Societies and Organisations

European Society of Medical Oncology
American Society of Clinical Oncology
American Association for the Advancement of Science
Association of Medical Oncologists of Hellas (Board)
British Association for Cancer Research
European Association for Cancer Research
American Association for Cancer Research
Hellenic Co-operative Oncology Group
European Organisation for the Research and Treatment of Cancer, Early Clinical Studies Group.
The American Society for Biochemistry and Molecular Biology
American Chemical Society

Prof. Carol Jean Wikstrand
Saba University School of Medicine, the Netherlands Antilles.

Professional training and academic career:

Visiting Investigator with Dr. Donald Bailey, Jackson Laboratory, Bar Harbor, ME January 1972 - June 1972
Post Doctorate in Tumour Immunology with Dr. G. Haughton, Department of Bacteriology and Immunology, University of North Carolina at Chapel Hill December, 1972 June, 1974
Laboratory Coordinator, Basic Microbiology, Department of Bacteriology and Immunology, University of North Carolina January, 1974 May, 1974
Research Associate, Tumour Immunology, with Dr. G. Haughton, University of North Carolina July, 1974 September, 1975
Research Associate, Department of Pathology, Duke University Medical Centre September 1975 1978
Member of the Graduate Faculty of the Duke University College of Arts and Sciences December 1976-present
Assistant Professor, Medical Research, Department of Pathology, Duke University Medical Centre October 1, 1978 December 1, 1987
Member, Comprehensive Cancer Centre Faculty, Duke University Medical Centre January, 1980 present
Assistant to the Director of Graduate Studies, Department of Pathology September, 1981 1993
Member, Admissions Committee for Graduate Studies, Department of Pathology September, 1981 1996
Member, Admissions Committee for Cell and Molecular Biology Program September 1985-present
Associate Professor, Medical Research, Department of Pathology, Duke University Medical Centre December 1, 1987 August 31, 2000
Director, Duke Comprehensive Cancer Centre Hybridoma Facility and Immunohistochemistry Shared Resource January 1997-present
Professor, Medical Research, Department of Pathology, Duke University Medical Centre September 1, 2000-2004

Prof. Torgny Stigbrand, MD, PhD
Umeå University, Sweden.

Positions and Employment:

1963-1965 Medical studies at University of Göteborg, Sweden
1965-1975 Medical studies at University of Umeå, Sweden, ending with licence as physician (MD)
1971 Ph.D in Medical Biochemistry, University of Umeå, Sweden
1973 -1990 Associated prof. and senior lecturer in Medical Biochemistry, University of Umeå, Sweden
1980 -1981 Postdoc at La Jolla Cancer Research Foundation, La Jolla, California, USA
1984 Received Fernströms Prize as outstanding young scientist, Umeå University
1980-1986 Chairman of the Medical Educational Committee at the Medical Faculty, Umeå University
1990 - present Appointed full Prof. in Immunochemistry, University of Umeå, Sweden
1986-1992 Vice dean of the Medical Faculty, University of Umeå, Sweden
1999 - present Editor-in-chief "Tumor Biology"
1970 - 2008 Supervisor for approx 30 MD or PhD-graduate students at the university

Publications:
297 publications has been produced during the 1971 - 2008.

Ongoing Research Support:
Stigbrand is presently supported from the Swedish "Cancerfonden" (Swedish Cancer Research Council project number 1387), the Lions Foundation in Umeå, University of Umeå and the County of Västerbotten The projects deal with radioimmunotargeting of tumors, tumor markers and immunochemistry.

Robert Waibel
Senior Research Scientist, Paul Scherer Institute, Switzerland.

Education:

1981 PhD in biochemistry, doctoral thesis at the Swiss Federal Institute of Technology (ETH), Zurich, Switzerland: "Isolation and characterization of cell-wall specific enzymes by use of controlled cross-linked enzymatic substrates."
1975 Diploma (B.S.) in chemistry, graduate thesis at the Dept. of Physical Chemistry, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland

Work Related Experience:

1996-present Senior Research Scientist, Centre for Radiopharmaceutical Research, Paul Scherer Institute, CH-5232 Villigen PSI, Switzerland
1995 Visiting research scientist at MRC, Center for Protein Engineering, University of Cambridge, UK: "Selecting new tumor surface antigens by human phage libraries."
1988-1995 Research Assistant Professor / Lecturer, Laboratory of Oncology, University Hospital Zurich, Switzerland. Group leader of "Biology of lung tumors"
1992 Visiting research scientist at the John Radcliffe Hospital, Molecular Immunology, University of Oxford, UK: "Expression cloning of surface antigens"
1985-1988 Research associate, Laboratory of Oncology, University Hospital Zurich, Switzerland
1983-1985 Research associate, Duke University, Medical Center, Durham, NC, USA: "Development and characterization of monoclonal antibodies which interfere with fertilization"
1981-1983 Post doctoral fellow/research associate, University of Western Michigan, Kalamazoo, MI, USA: "Development of a new test system for diagnosis of mutations in humans"
1976-1977 Research assistant, Swiss Federal Institute of Technology (ETH), Zurich

Cancer Conferences